Table I. Perioperative Chemotherapy Regimens in Patients with Low- and High-Grade Appendiceal Mucinous Carcinoma Peritonei.

Low-grade	Pre-op	Adjuvant	Pre-op + adjuvant
	(n = 13)	(n = 9)	(n = 0)
Fluorpyrimidine alone	4 (31%)	2 (22%)
Fluorpyrimidine + oxaliplatin	5 (39%)	4 (44%)
Fluorpyrimidine + irinotecan	2 (15%)	1 (11%)
Other or unknown	2 (15%)	2 (22%)
Addition of bevacizamab	7 (54%)	2 (22%)
Addition of cetuximab	1 (7%)	0

High-grade	n = 37	n = 22	n = 11
			Pre-op	Adjuvant
Fluorpyrimidine alone	3 (8%)	1 (4%)	0	4 (36%)
Fluorpyrimidine + oxaliplatin	28 (74%)	16 (73%)	9 (82%)	4 (36%)
Fluorpyrimidine + irinotecan	3 (8%)	3 (14%)	1 (9%)	2 (18%)
Other or unknown	3 (8%)	2 (9%)	1 (9%)	1 (9%)
Addition of bevacizamab	19 (50%)	5 (23%)	7 (64%)	5 (45%)
Addition of cetuximab/panitumumab	0	1 (5%)	1 (9%)	1 (9%)